J&J’s One-Dose COVID-19 Vaccine Shows 72% Efficacy in the US

Results from Phase 3 clinical trials on Johnson & Johnson’s (J&J) one-dose COVID-19 vaccine demonstrated 72% effectiveness against moderate to severe COVID-19-related illness in the United States. However, this rate dropped to 57% in trials conducted in South Africa, which suggests the vaccine is less able to fight off the new variant that is highly present in the region. The effectiveness of the J&J vaccine is high enough to meet the US Food and Drug Administration’s requirements for Emergency Use Authorization but is lower than the Pfizer and Moderna vaccines, which are approximately 95% effective. However, the J&J vaccine requires only one dose and does not need sub-zero storage, which could help efforts to get more individuals vaccinated as quickly as possible. Click here to read more.